Treatment of classical type kaposi's sarcoma with paclitaxel

S. C. Chao, J. Y.Y. Lee, C. J. Tsao

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Paclitaxel has recently been shown to be effective in treating acquired immunodeficiency syndrome-associated Kaposi's sarcoma. We report good therapeutic effects of paclitaxel in two patients with classical form Kaposi's sarcoma (KS) which had poor or partial response to chemotherapy (vincristine, vinblastine, oncovin, bleomycin, epirubicin, dactinomycin, decarbazine) and interferon alpha-2b. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. The experience suggests that paclitaxel is an effective alternative in the treatment of classical form Kaposi's sarcoma.

Original languageEnglish
Pages (from-to)571-574
Number of pages4
JournalAnticancer research
Issue number1 B
Publication statusPublished - 2001 Apr 17

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of classical type kaposi's sarcoma with paclitaxel'. Together they form a unique fingerprint.

Cite this